New stocks news | Stem cell therapy development company Pollon Life secretly applied for Hong Kong listing, raising about 300 million US dollars.

According to media reports, China's stem cell therapy development company Pollon Life has applied to go public in Hong Kong in a confidential manner, raising about $300 million. Informed sources indicated that Pollon Life has received support from Jack Ma's Yunfeng Capital and is collaborating with China International Capital Corporation, CICC, and UBS Group to advance its listing plans. Discussions are still ongoing, and details such as the IPO scale may be adjusted. Previously known as Poson Excellence Biotechnology, Pollon Life has developed China's first approved stem cell therapy, the Amymetois injection, which is indicated for the treatment of acute graft-versus-host disease in patients over 14 years old with predominantly digestive system involvement who have failed hormone therapy.